Scientists ID protein that regulates cellular trafficking, potential for anti-cancer therapy

Sep 22, 2013

Molecular microbiologists at the University of Southern California (USC) have uncovered intricate regulatory mechanisms within the cell that could lead to novel therapeutics for the treatment of cancer and other diseases. Their findings, which have long-standing significance in the basic understanding of cell biology, appear in the journal Nature Cell Biology.

"Our research reveals a new regulatory mechanism that coordinates two distinct intracellular processes that are critical to and disease development," said Chengyu Liang, M.D., Ph.D., a member of the USC Norris Comprehensive Cancer Center and principal investigator of the study.

The endoplasmic reticulum (ER) and Golgi apparatus are cellular organelles in eurkaryotic organisms where proteins are synthesized and packaged for secretion through the body. The trafficking of proteins between the ER and Golgi must be tightly modulated to maintain the health of the cell and prevent diseases like cancer from taking hold.

"Interest in the role of ER-Golgi network during cancer cell death has been gaining momentum," said Shanshan He, Ph.D., research associate at the Keck School of Medicine of USC and one of the study's first authors. "In this study, we identified a novel regulatory factor for the Golgi-ER retrograde transport and a new mechanistic connection between the physiological trafficking and the autophagic transportation of cellular material."

The researchers discovered that the UV irradiation resistance-associated gene protein (UVRAG), which has been implicated in the suppression of colon and breast cancer, coordinates trafficking of proteins between the ER and Golgi apparatus and also autophagy, the natural process of breaking down cellular components.

"Given that the ER-Golgi network is often dismantled in malignant conditions and that UVRAG is intensively involved in different types of human cancers, this study gives us a new avenue to investigate anti- that target UVRAG and/or the ER-Golgi pathway in cancer and other relevant diseases," Liang said.

Explore further: New class of insecticides offers safer, more targeted mosquito control

More information: He, S., et al. (2013). PI(3)P-bound UVRAG coordinates Golgi–ER retrograde and Atg9 transport by differential interactions with the ER tether and the Beclin 1 complex. Nature Cell Biology. Published online Sept. 22, 2013; DOI: 10.1038/ncb2848

Related Stories

First genome-wide assessment of secretion in human cells

Jun 04, 2012

(Phys.org) -- An international collaboration between scientists in University College Dublin and the European Molecular Biology Laboratory (EMBL) has revealed for the first time that 15% of the proteins encoded ...

Worm studies shed light on human cancers

Apr 21, 2011

(PhysOrg.com) -- Research in the worm is shedding light on a protein associated with a number of different human cancers, and may point to a highly targeted way to treat them.

Recommended for you

The vital question: Why is life the way it is?

15 hours ago

The Vital Question: Why is life the way it is? is a new book by Nick Lane that is due out on April 23rd. His question is not one for a static answer but rather one for a series of ever sharper explanations—explanations that a ...

Food poisoning: New detection method for bacterial toxin

16 hours ago

The Bacillus cereus bacteria is one of the potential causes of food poisoning. Indeed, a recent study in Analytical and Bioanalytical Chemistry shows that this versatile pathogen produces 19 different varian ...

Detailing heterochromatin formation at the onset of life

17 hours ago

Antoine Peters and his group at the Friedrich Miescher Institute for Biomedical Research (FMI) have elucidated the mechanisms controlling the packaging of chromatin in the early embryo. They have identified ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.